While Luminal A, Luminal B, and HER2‐positive subtypes of breast cancer typically exhibit favorable treatment outcomes, significant challenges persist concerning mortality rates, recurrence, and treatment‐related adverse effects, particularly in TNBC, which is characterized by limited therapeutic options and poorer prognoses. The gene discussed is ERBB2; the disease is breast cancer.